2025-05-17 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data you provided. The report is in English, includes key numbers upfront, and then provides a brief analysis for each section and a final summary.

## RXRX Stock Analysis Report

**Ticker:** RXRX
**Company Name:** Recursion Pharmaceuticals Inc

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover, develop, and commercialize novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -57.49%
*   **VOO Cumulative Return:** 23.36%
*   **Divergence:**
    *   **Current Divergence:** -80.86% (RXRX is lagging VOO significantly)
    *   **Divergence Range:** (Min: -83.0, Max: 28.3)
    *   **Relative Divergence:** 1.9  (RXRX's current divergence is near its worst historical level relative to VOO.)

**Analysis of Alpha, Beta, CAGR, and MDD:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| :----------- | :----- | :----- | :------ | :----- | :----- |
| 2021-2023 | 5.0% | 73.6% | -10.0% | -0.0 | 4.0    |
| 2022-2024 | 0.0% | 73.6% | -21.0% | 0.0    | 2.8    |
| 2023-2025 | -6.0% | 73.6% | -29.0% | -0.0 | 1.9    |

**Analysis:**

*   **Underperformance:** The significant negative alpha across all periods indicates substantial underperformance relative to the market. This means the stock has not delivered risk-adjusted returns, as it is losing more relative to the benchmark than the market fluctuations would suggest.
*   **High Volatility:** The Maximum Drawdown (MDD) is consistently high at 73.6% across all time frames, indicating significant volatility and risk. Investors have experienced substantial peak-to-trough declines.
*   **Beta Neutrality:** A Beta of close to zero suggests that the stock's returns are uncorrelated with the broader market (S&P 500). This could imply that the stock is driven more by company-specific factors rather than overall market trends.
*   **Declining Market Cap:** The market capitalization has decreased from $4.0B to $1.9B, reflecting investor concerns and potentially declining valuation.

### 2. Recent Stock Price Movements

*   **Current Price:** $4.56
*   **Previous Close:** $4.25
*   **Change:** +7.29% (Significant upward movement)
*   **5-Day Moving Average:** 4.454
*   **20-Day Moving Average:** 5.027
*   **60-Day Moving Average:** 5.7938

**Analysis:**

The stock has experienced a significant 7.29% jump in price, potentially signaling a short-term rebound. However, the current price is still below the 20-day and 60-day moving averages, suggesting the stock is still in a downtrend despite the recent surge. The recent movement needs to be monitored to ascertain whether the uptrend can be sustained.

### 3. Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3475 (Low Risk)
*   **RSI:** 31.12 (Approaching Oversold)
*   **PPO:** -0.82
*   **Recent (20-day) Relative Divergence Change:** 1.2 (Positive, indicating short-term improvement)
*   **Expected Return:** -1873.4% (Long-term, relative to S&P 500 if investing at this time)

**Analysis:**

*   **MRI:** The low MRI suggests that from a risk perspective the current market conditions may provide more favorable circumstances for investment.
*   **RSI:** The RSI suggests the stock may be oversold and could experience a bounce.
*   **PPO:** The negative PPO suggests a bearish trend, but it's close to zero, indicating potential stabilization.
*   **Recent Divergence Change:** The short-term increase in relative divergence (1.2) aligns with the recent price jump, potentially indicating a short-term positive trend relative to the S&P 500.
*   **Expected Return:** The significantly negative expected return implies that, based on current conditions, the stock is not expected to outperform the S&P 500 over the long term.
*   **Sudden Price Increase:** Considering the +7.29% change from the previous close, there has been a noteworthy recent price jump, suggesting that there are significant short-term volatility issues.

### 4. Recent News & Significant Events

*   **2025-05-16:** Major business developments, regulatory changes, or market events.
*   **2025-05-14:** Analyst discussion of recent performance and outlook.
*   **2025-05-15:** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **2025-05-13:** Market experts highlighting both risks and opportunities.

**Analysis:**

The news indicates significant events impacting the stock. Monitor company announcements, news articles, and analyst reports to understand the specific factors driving volatility and potential future performance.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue  |
| :---------- | :----- | :------- |
| 2025-05-05 | -0.50 | $0.01B  |
| 2024-11-06 | -0.34 | $0.03B  |
| 2024-08-08 | -0.40 | $0.01B  |
| 2024-05-09 | -0.39 | $0.01B  |
| 2025-05-05 | -0.39 | $0.01B  |

**Analysis:**

*   **Negative EPS:** Recursion Pharmaceuticals consistently reports negative Earnings Per Share (EPS) across all listed quarters. This indicates that the company is not generating profits.
*   **Revenue Trend:** While there is some variability in revenue, the figures are generally low. A slight increase in the quarter ending in November 2024 might be something to watch for future trends.
*   **Financial Instability:** The company's negative earnings and low revenue indicate potential financial instability, which may deter investors unless there are significant positive changes in the future.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :----------- | :------- | :-------------- |
| 2025-03-31 | $0.01B  | -47.31%         |
| 2024-12-31 | $0.00B  | -183.62%        |
| 2024-09-30 | $0.03B  | 53.69%          |
| 2024-06-30 | $0.01B  | 36.14%          |
| 2024-03-31 | $0.01B  | 17.23%          |

**Capital and Profitability:**

| Quarter    | Equity | ROE        |
| :----------- | :------- | :----------- |
| 2025-03-31 | $0.93B  | -21.68%    |
| 2024-12-31 | $1.03B  | -17.29%    |
| 2024-09-30 | $0.52B  | -18.27%    |
| 2024-06-30 | $0.58B  | -16.69%    |
| 2024-03-31 | $0.40B  | -22.78%    |

**Analysis:**

*   **Revenue and Profit Margin:** Revenue is fluctuating, with a significant increase in Q3 2024. Profit margins are mostly negative, except for Q3 and Q2 2024, which show positive margins but are not consistent. The high negative profit margin in Q4 2024 is concerning.
*   **Capital and Profitability:** Equity has been fluctuating, indicating potential capital management issues. Return on Equity (ROE) is consistently negative, reflecting the company's inability to generate profits from its equity.

### 7. Overall Summary

Recursion Pharmaceuticals (RXRX) exhibits several concerning financial and market indicators. The company has significantly underperformed the S&P 500, as shown by a large negative divergence and negative alpha. The high MDD reflects substantial volatility. While the MRI indicates low market risk, the RSI suggests the stock might be oversold. The negative expected return and consistently negative EPS, coupled with fluctuating revenue and negative profit margins, indicate financial instability. Recent news suggests ongoing market events and analyst discussions impacting the stock. Investors should closely monitor company-specific developments, earnings reports, and market conditions before considering investment in RXRX. The recent price jump needs to be evaluated for sustainability.
